NEWS

News

May

06/05/2021

Philogen S.p.A. will announce its maiden First Quarter 2021 Results on Wednesday 12th May 2021

A virtual briefing will be hosted for sell-side analysts at 10:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021

  PRESS RELEASE - Notice of Q1 Results

April

13/04/2021

Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS

Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs
OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer 

  PRESS RELEASE - PNAS

12/04/2021

Philogen announces publication of the construction and application of an innovative DNA- encoded chemical library in Nature Chemistry

Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library.
Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications.
 

 

  PRESS RELEASE - NATURE CHEMISTRY

March

08/03/2021

Philogen will be attending the digital World ADC Europe Conference from March 8 to 11, 2021.
Dr. Samuele Cazzamalli - Head of Small Molecule Therapeutics - will give a Plenary Lecture on: Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting”.

January

22/01/2021

Philochem announces a publication entitled: “Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of Small Molecule-Drug Conjugates targeting Carbonic Anhydrase IX”
Link to Paper

04/01/2021

Philochem is happy to announce the start of an Innosuissecollaboration with ETH Zurich for the development of Macrocyclic DualPharmacophore DNA-Encoded Chemical Libraries.
The partners will synthesize andvalidate macrocycle-based libraries comprising more than one billion compounds.
These libraries will have a great potential for the identification of ligandsagainst target proteins of biomedical interest with antibody-like properties

x

By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy
X